This article was first published in Kluwer Patent Blog [November 2026].
The UK approach to plausibility and, in particular, the decisions in relation to apixaban1 and dapagliflozin2, have ensured that the UK continues to be a fertile hunting ground for generic companies seeking to challenge compound patents in order to carve out early launch opportunities.
On 17 November 2026, Meade LJ (recently promoted to the Court of Appeal but sitting as a Patents Court Judge) handed down another decision on plausibility in Dr Reddys v Boehringer3. The case concerned the validity and infringement of two patents relating to empagliflozin, active ingredient in Boehringer’s blockbuster SGLT2 inhibitor, Jardiance®: (i) a compound patent (EP 1 730 131, “the Patent”) on which an SPC is based, which expires in November 2029; and (ii) a patent to a crystalline form of empagliflozin, which expired in May 2026 (EP 1 888 552, the “Polymorph Patent”). This update primarily focuses on the plausibility case against the Patent.
It was common ground that the Patent did not disclose experimental data to support that the claimed compounds would act as SGLT inhibitors. Meade LJ uncontroversially accepted Boehringer’s contention that following Warner-Lambert4, such data is not a prerequisite for plausibility; a verbal or qualitative statement of a result may be enough and plausibility can in principle be established by a theory or rationale. But did the Patent offer such a disclosure?
Boehringer’s principal argument was that it would be clear to the skilled team that the Patent’s identification of 15 preferred compounds must have been based on actual or potential SGLT inhibition. Meade LJ accepted this but considered that the decisive question was whether the compounds were disclosed as having been tested for SGLT activity, an exercise that the Judge noted was “crucially different… from trying to assess what as a matter of fact the patentee is likely to have done, a sort of detective work” Ultimately, the Judge could not identify a single passage in the specification which by itself disclosed that any SGLT activity test was done. Accordingly, there was no plausible disclosure.
This case provides an important contrast with the judgment in Accord v Novartis5. Both cases involved a plausibility attack in the absence of experimental data in the patent, but the qualitative disclosure that actual work had been done was enough to get Novartis over the threshold and the absence of such a disclosure was fatal for Boehringer.
Interestingly, Meade LJ noted that while he is bound to the ab initio plausibility standard, plausibility is an issue that the Supreme Court may wish to take another look at if the right case comes before it. Accordingly, at the request of the parties, Meade LJ went on to make contingent findings of fact that were potentially relevant to an assessment under the ab initio implausibility test, which would only be relevant if the Supreme Court changes the law. In this regard, the Judge found that Dr Reddys had provided support for “a positive reason to doubt” whether empagliflozin would have SGLT activity. He also made findings concerning the work that Boehringer had actually done despite noting that he was “comparatively more dubious as to what legal standard the facts alleged by BI would ever go.”
It will be interesting to see how the appeal proceedings develop and whether this case will be “the right case” for the Supreme Court to revisit plausibility, an eventuality that Meade LJ appears to consider likely and desirable. On the one hand, on the basis of the contingent findings of Meade LJ on Dr Reddys case, it arguably doesn’t matter which test is applied. On the other, the picture could be very different if the skilled team is entitled to take the actual work done into consideration.
It is also interesting to note that the Polymorph Patent was held valid and infringed. Dr Reddys has been the subject of a preliminary injunction since November 20256. Accordingly, subject to any appeal, Boehringer will not be liable for damages to Dr Reddys (or the Department of Health) for the period between November 2025 and May 2026. It will be interesting to see if Boehringer seeks to maintain the PI against Dr Reddys based on the Patent (or obtain PIs against any other generics seeking to launch7) pending the outcome of any appeal.
Footnotes
[1]Sandoz v BMS [2023] EWCA Civ 472
[2] AstraZeneca v Glenmark [2025] EWCA Civ 480
[3] Dr Reddys v Boehringer [2026] EWHC 2944 (Pat)
[4] Warner-Lambert v Mylan [2018] UKSC 56
[5] Accord v Novartis [2026] EWHC 2127 (Pat)
[6] Dr Reddys v Boehringer [2025] EWHC 2834 (Pat)
[7] We understand that Boehringer recently initiated proceedings against both Teva and Sandoz in the Patents Court (Claims HP-2026-000043 and HP-2026-000045).

/Passle/5f3d6e345354880e28b1fb63/MediaLibrary/Images/2025-09-29-13-48-10-128-68da8e1af6347a2c4b96de4e.png)
/Passle/5f3d6e345354880e28b1fb63/SearchServiceImages/2026-11-19-11-42-58-073-6afee0c2ff5130799d07a913.jpg)
/Passle/5f3d6e345354880e28b1fb63/MediaLibrary/Images/2026-10-14-13-50-16-944-6acf8898a81c552c14eaf07b.jpg)
/Passle/5f3d6e345354880e28b1fb63/SearchServiceImages/2026-11-12-17-32-40-845-6af5f8381d08c17997a20ca9.jpg)